Newswise
Cure8 news brief
Polydatin Targets KEAP1 to Rebalance Gut Immunity in Ulcerative Colitis
Research and clinical trials
Basic Science
Researchers
Clinicians
Adult patients
Ulcerative colitis
Inflammatory bowel disease
Why This Matters
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This could point to a new biological pathway for future drug development.
Who Should Pay Attention
Researchers studying IBD immune mechanisms or new therapeutics, clinicians interested in emerging preclinical findings, and patients curious about future research directions in ulcerative colitis.
Study Snapshot
Story typeResearch news
Evidence typePress release
Source depthSource summary
What To Know
The study links polydatin’s activity to binding KEAP1 and activating NFE2L2 (NRF2) signaling, which lowered reactive oxygen species and shifted T‑cell responses away from inflammatory Th1/Th17 toward regulatory T cells in experimental models.
The report describes reduced mucosal injury and disease severity in mice treated with the HDEC formulation and polydatin. The evidence reported here is preclinical: mouse experiments and ex vivo human cell or tissue observations.
This suggests a potential mechanism and a candidate compound for further research, but it does not establish safety or effectiveness in people with UC. If you are reading this as a patient, this is not treatment advice. Clinical trials would be needed to determine whether polydatin or HDEC is safe, effective, and available as an IBD therapy.
Keep In Mind
The article summarizes preclinical (mouse and ex vivo human sample) research reported by Newswise; it does not report clinical trial results. Findings in animal models and tissue samples do not guarantee benefit or safety in people. Further studies, including controlled clinical trials, would be required before any clinical use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Press release
Evidence type derived from source or registry metadata.
PublicationNewswise
PublisherNewswise MedNews RSS
AuthorsChinese Academy of Sciences
Indexed viaNewswise
Source typeResearch news
PublishedAug 17, 2026, 3:05 PM
Content availableSource summary
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor.
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
Nrf2 suppresses inflammatory Th1/Th17 responses and promotes regulatory T cell differentiation by CD4+ T cells to alleviate ulcerative colitis 2260871
This study suggests that boosting Nrf2 activity in CD4+ T cells can reduce inflammatory Th1/Th17 responses and increase regulatory T cells, which may help control colonic inflammation in ulcerative colitis.
Poricoic acid a ameliorates ulcerative colitis via AMPK/PPARγ pathway-dependent cellular senescence inhibition and concomitant gut microbiota-metabolome modulation.
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...